Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have attracted much attention because of their significant hypoglycemic and weight-loss effects. Previous preparations can only be subcutaneously injected. Oral administration of GLP-1RAs semaglutide helps to broaden treatment options, but its safety in the real world still needs to be observed. This study is based on FDA adverse event reporting system (FAERS) database to mine adverse drug events (ADE) of oral semaglutide, and provide references for the clinical safe use of this drug. METHODS: To analyze the signal quality of oral semaglutide, which is a drug used in the FAERS database from the third quarter of 2019 to the third quarter of 2023, we collected ADE data and performed data mining by using disproportionate analysis. Then, we standardized the data and used a variety of signal-quantification techniques, including reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian belief propagation neural network (BCPNN), and multiple empirical Bayesian gamma Poisson contractions (MGPS), for further analysis. RESULTS: We screened 2398 reports on the use of semaglutide tablets, involving a total of 5653 ADE. These reports were mainly submitted by consumers, and the reporting country was mainly the United States. A total of 23 system organ classes (SOC) and 93 preferred terms (PT) were mined for the signals of semaglutide tablets. The three most common SOC were gastrointestinal disorders, general disorders and administration site conditions, and investigations. At the PT level, metabolism and nutrition disorders exhibit the highest number of signals, with the top three being thyroid cyst, acute cholecystitis, and ketosis. Gastrointestinal disorders rank second, primarily involving eructation, pancreatitis, impaired gastric emptying, and regurgitation. In addition, vith nerve paralysis occurs and the signal intensity is high. CONCLUSIONS: Our study provides a deeper and broader understanding of the safety of oral semaglutide. The results of the ROR, PRR, BCPNN, and MGPS algorithms exhibit high consistency, with metabolism and nutrition-related disorders having the highest number of signals. The conclusions align with the technical specifications of the product. Notably, other unexpected effects are reported, including acute cholecystitis, paralysis of the abducens nerve, and positional vertigo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune system disorders were investigated in one publication, but there were no events reported [102].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Although the clinical trial clearly reported that semaglutide tablets have the risk of acute pancreatitis and pancreatic cancer [24, 26], another study [27] did not observe clear evidence of pancreatitis risk.”
The Global Burden of Cardiovascular Diseases and Risk
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.005 · Cited by 2,217
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 1×
“Oral semaglutide has been confirmed to have a clear cardiovascular benefit [32].”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 2×
“A systematic review and meta-analysis of randomized trials also suggested that there was a risk of key safety outcomes (severe hypoglycemia, retinopathy, or pancreatic adverse reactions) with GLP-1RAs, but there was no increase [30].”
InfluentialA Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476 · cited 1×
“In this study, four disproportionate methods were used to mine drug ADE signals: reported odds ratio (ROR) [8], proportional reporting ratio (PRR) [9], Bayesian belief propagation neural network (BCPNN) [10], and multiple empirical Bayesian gamma Poisson contractions (MGPS) [11].”
The reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111 · cited 1×
“In this study, four disproportionate methods were used to mine drug ADE signals: reported odds ratio (ROR) [8], proportional reporting ratio (PRR) [9], Bayesian belief propagation neural network (BCPNN) [10], and multiple empirical Bayesian gamma Poisson contractions (MGPS) [11].”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662 · cited 1×
“Because of its excellent curative effect, it is recommended by many diabetes prevention and treatment guidelines [13–15].”
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 1×
“Based on PIONEER 1–10 global clinical trials [17–20], it has been confirmed that it can significantly improve blood glucose control and weight loss in patients with type 2 diabetes, and can also improve cardiovascular outcomes, which has attracted much attention at present.”
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · cited 2×
“Although the clinical trial clearly reported that semaglutide tablets have the risk of acute pancreatitis and pancreatic cancer [24, 26], another study [27] did not observe clear evidence of pancreatitis risk.”
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351 · cited 1×
“Studies have shown that different degrees of impaired renal function have no significant impact on its pharmacokinetic characteristics, and there is no need to adjust the dose for patients with T2DM with mild, moderate, and severe renal dysfunction [31].”
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248 · cited 1×
“Because of its excellent curative effect, it is recommended by many diabetes prevention and treatment guidelines [13–15].”
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.044 · Cited by 243 · cited 2×
“It may also lead to the diabetes treat-ment group starting GLP-1 receptor agonist treatment earlier [5].”
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155 · cited 1×
“ROR reported odds ratio, PT preferred terms, FAERS FDA adverse event reporting system, CI confidence interval also showed that semaglutide tablets do not increase the risk of pancreatitis [28, 29].”
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145 · cited 1×
“GLP-1RAs drugs can delay gastric emptying and inhibit appetite, so the most common adverse events are gastrointestinal adverse events [23], including nausea, vomiting diarrhea and constipation.”
Yan, J., Zhang, H., Yin, Y., Li, J., Tang, Y., Purkayastha, S., Li, L., & Cai, D. (2014) · Nature Medicine · doi:10.1038/nm.3616 · Cited by 142 · cited 1×
“Obesity will aggravate and lead to hyper-glycemia [1, 2].”
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135 · cited 1×
“Studies have found that the absorption of oral semaglutide, a glucagon-like peptide-1 analog, is co formulated long half-life of oral semaglutide, once-daily administration can achieve a stable steady-state concentration [22].”
Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database
Jiang, Y., Zhou, L., Shen, Y., Zhou, Q., Ji, Y., & Zhu, H. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.025 · Cited by 130 · cited 1×
“By comparing the target ADE occurrence ratio of the target drug with that of all other drugs, if the ratio was greater than the set threshold, it was called imbalance, suggesting the generation of potential ADE signals [12].”
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Sarangdhar, M., Tabar, S., Schmidt, C., Kushwaha, A., Shah, K., Dahlquist, J. E., Jegga, A. G., & Aronow, B. J. (2016) · Nature Biotechnology · doi:10.1038/nbt.3623 · Cited by 82 · cited 1×
“FAERS provides a platform for collecting and analyzing ADE related to drug utilization [7].”
Shi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50 · cited 1×
“ROR reported odds ratio, PT preferred terms, FAERS FDA adverse event reporting system, CI confidence interval also showed that semaglutide tablets do not increase the risk of pancreatitis [28, 29].”
Heo, S., & Jung, I. (2020) · Statistics in Medicine · doi:10.1002/sim.8745 · Cited by 35 · cited 1×
“In this study, four disproportionate methods were used to mine drug ADE signals: reported odds ratio (ROR) [8], proportional reporting ratio (PRR) [9], Bayesian belief propagation neural network (BCPNN) [10], and multiple empirical Bayesian gamma Poisson contractions (MGPS) [11].”
Vascular repair and regeneration in cardiometabolic diseases
Hess, D. A., Verma, S., Bhatt, D. L., Bakbak, E., Terenzi, D. C., Puar, P., & Cosentino, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab758 · Cited by 31 · cited 1×
“Several studies have confirmed [3, 4] that T2DM and obesity are closely related to cardiovascular complications, which bring a heavy financial burden to the global health care system.”
Testing and Implementing Signal Impact Analysis in a Regulatory Setting: Results of a Pilot Study
Heeley, E. L., WALLER, P. C., & Moseley, J. (2005) · Drug Safety · doi:10.2165/00002018-200528100-00006 · Cited by 21 · cited 1×
“In this study, four disproportionate methods were used to mine drug ADE signals: reported odds ratio (ROR) [8], proportional reporting ratio (PRR) [9], Bayesian belief propagation neural network (BCPNN) [10], and multiple empirical Bayesian gamma Poisson contractions (MGPS) [11].”
Safari, S., Abdoli, M., Amini, M., Aminorroaya, A., & Feizi, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91229-9 · Cited by 6 · cited 1×
“Obesity will aggravate and lead to hyper-glycemia [1, 2].”
Research works printed but not linked: 3
- Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - PubMed. https://pubmed.ncbi.nlm.nih.gov/36148880/. Accessed 3 Mar 2024. PMC10008140 36148880
- Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial - PubMed. https://pubmed.ncbi.nlm.nih.gov/29049653/. PMC5817971 29049653
- PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes - PubMed. https://pubmed.ncbi.nlm.nih.gov/31186300/. Accessed 3 Mar 2024. 31186300
Cited by
Tao, C., Zhang, Y., Wan, T., Zhao, W., Chen, J., Wang, K., Yang, L., Wang, G., Ding, Q., Shang, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1557691 · Cited by 20
Self-citationWang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., Zhou, L., & Zou, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530697 · Cited by 17
Dai, X., Feng, S., & Li, T. X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107720 · Cited by 11
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 13
“Rarely other unexpected effects of semaglutide are reported, including acute cholecystitis, paralysis of the abducens nerve, and positional vertigo [ 105 ].”
Jiang, Y., Zhang, S., Pan, L., Leng, J., Zhou, T., Liu, M., Li, L., & Zhao, W. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133333 · Cited by 11
Metadata
- Authors
- Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J.
- Affiliations
- Guangxi Medical University (CN)
- Ningxia Medical University (CN)
- Corresponding author
- Luo, Changjun
- Chen, Junan
- ORCID
- Venue
- Diabetes Therapy
- Published
- 2024-05-22
- Volume
- 15
- Issue
- 8
- Pages
- 1717-1733
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC11263519
- OpenAlex
- W4398211111
- Cited by
- 26
- References
- 29
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 2
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- the National Natural Science Foundation of China (No.82360052)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, GLP-1 receptor agonists, adverse drug reactions, drug safety, adverse event signals, thyroid cysts, acute cholecystitis, ketosis, pancreatitis, impaired gastric emptying, abducens nerve palsy, positional vertigo, drug-induced hypoglycemia, drug-induced weight loss, FDA Adverse Event Reporting System, disproportionality analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.